Everolimus is a type of medicine used to prevent organ rejection after a transplant, like a heart or kidney transplant. It works by stopping the body's cells from growing too much. It's also used to treat certain types of cancer.
Every report comes from a Lived member, sent anonymously.
Have you tried Everolimus for Tuberous Sclerosis?
Everolimus is a prescription medicine, taken by mouth, that slows the growth and multiplication of cells. It is used in two very different areas of medicine, under different brand names, at different doses and on different schedules, so it matters which product a person has been prescribed. As Afinitor (also sold as generic everolimus tablets), it is a targeted cancer treatment. It is approved for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer, taken together with the hormone therapy exemestane once letrozole or anastrozole has stopped working. It is also approved for adults with advanced kidney cancer (renal cell carcinoma) after treatment with sunitinib or sorafenib, and for adults with certain neuroendocrine tumors, slow-growing tumors that begin in hormone-producing cells of the pancreas, digestive tract or lungs, when they are growing and cannot be removed by surgery. Afinitor also treats growths caused by tuberous sclerosis complex (TSC), a genetic condition that causes noncancerous tumors in many organs. These include kidney tumors called angiomyolipomas in adults who do not need immediate surgery, and a brain tumor called subependymal giant cell astrocytoma (SEGA) in adults and children aged 1 and older when it cannot be fully removed. Afinitor Disperz, a version made to dissolve in water, is the form approved as an add-on treatment for TSC-related partial-onset seizures (seizures that start in one area of the brain) in people aged 2 and older. As Zortress, everolimus is an anti-rejection medicine (an immunosuppressant) for adults who have received a kidney or liver transplant. It is always combined with other anti-rejection drugs, including a reduced dose of cyclosporine after a kidney transplant or tacrolimus after a liver transplant, plus a steroid. It is not recommended after a heart transplant.
Inside cells, a protein called mTOR (mammalian target of rapamycin) acts as a control hub that tells cells when to grow and divide. Everolimus blocks mTOR. It is a close chemical relative of sirolimus (also called rapamycin), an older drug that works the same way. What that achieves depends on the setting. In cancer, blocking mTOR slows tumor cell growth and reduces the signals tumors use to build new blood vessels. In TSC, the faulty genes that cause the condition leave mTOR switched on too much, which drives tumor growth and contributes to seizures; everolimus turns down that overactivity, which is why it can shrink TSC tumors. After a transplant, blocking mTOR stops the immune system's T and B cells from multiplying in response to the new organ, lowering the chance that the body attacks it. The same effect on immune cells is why everolimus raises the risk of infection whichever reason it is taken for.
Everolimus is taken by mouth, and the routine depends on the product and the reason for treatment. For cancer and TSC kidney tumors, Afinitor tablets are usually taken once a day at the same time each day, either always with food or always without. They are swallowed whole with a glass of water and should not be broken or crushed. Afinitor Disperz is given only as a liquid: the tablets are placed in a small amount of water in an oral syringe or small glass, left for a few minutes to break apart, and taken right away. Afinitor and Afinitor Disperz should not be combined to make up a dose, and anyone preparing Disperz for another person should wear gloves. For TSC brain tumors and seizures, the dose is based on body size and then adjusted using a trough level, a blood test of the lowest amount of everolimus in the blood, taken just before the next dose. Trough levels are rechecked after dose changes, after switching forms, and when interacting medicines are started or stopped. Zortress is taken twice a day, about 12 hours apart, at the same time as cyclosporine or tacrolimus and consistently with or without food. The tablets are swallowed whole and not crushed. The transplant team checks trough levels of both everolimus and the partner drug and adjusts the doses to keep them in range. If a once-daily Afinitor dose is missed, it can still be taken up to 6 hours late; after that, skip it and take the next dose at the usual time. Never double a dose. People with liver problems usually need a lower dose, and doses are often paused or reduced to manage side effects.
Mouth sores and ulcers (stomatitis) are the side effect most people on Afinitor notice. They affect roughly half or more of people in cancer and TSC treatment, usually appear within the first 8 weeks, and can make eating painful. Starting an alcohol-free dexamethasone (steroid) mouthwash, swished and spat out, on the same day as everolimus lowers how often and how badly they occur. Mouth rinses containing alcohol, hydrogen peroxide, iodine or thyme can make sores worse. Other common effects in cancer treatment include infections, rash, tiredness and weakness, diarrhea, swelling of the hands or legs, stomach pain, nausea, fever, cough, headache and poor appetite. After a transplant, swelling, constipation, high blood pressure, nausea, anemia (low red blood cells) and urinary tract infections are common. Everolimus also often raises blood sugar, cholesterol and triglycerides, and can lower blood counts, so regular blood tests are part of treatment. A few effects need quick action. Everolimus can inflame the lungs without any infection (non-infectious pneumonitis), which has occasionally been fatal; a new or worsening cough or shortness of breath should be reported to the care team right away. Because everolimus weakens immune defenses, infections can become serious quickly, so fever, chills or other signs of infection also call for a prompt call. Sudden swelling of the face, lips, tongue or throat, or trouble breathing or swallowing, can be a severe allergic reaction or angioedema and needs emergency care. Everolimus can also strain the kidneys and slow wound healing, which the care team watches for with kidney tests and around any surgery.
The body clears everolimus through a liver enzyme called CYP3A4 and a drug transport pump called P-glycoprotein, so many medicines change its level. Drugs that strongly block this pathway, such as the antifungal ketoconazole, can multiply everolimus levels many times over and are generally avoided. Others push levels down and can make it less effective, including the seizure medicines carbamazepine and phenytoin, the tuberculosis antibiotic rifampin and the herbal supplement St. John's wort. Grapefruit and grapefruit juice raise levels and should be avoided, and cannabidiol (CBD) can raise them too. Check with the prescriber or pharmacist before starting or stopping any medicine or supplement, since the dose may need to change. ACE inhibitors, a common family of blood pressure and heart medicines, increase the risk of angioedema with everolimus. In cancer trials it occurred in 6.8% of people taking both, compared with 1.3% of those on an ACE inhibitor without everolimus, and the Afinitor label advises avoiding the combination. Live vaccines, such as the nasal flu vaccine, MMR (measles, mumps, rubella), chickenpox and yellow fever vaccines, should be avoided during treatment, as should close contact with people who have just received one. Children starting Afinitor should complete their routine vaccines beforehand when possible. Everolimus is usually paused at least a week before planned surgery because it slows healing, and the care team should know about past or planned radiation therapy, since everolimus can make radiation reactions more severe. People who have had a serious allergic reaction to everolimus, sirolimus or a related drug should not take it. Everolimus can harm an unborn baby. Women who could become pregnant should use effective birth control during treatment and for 8 weeks after the last dose; with Afinitor, men whose partners could become pregnant should use it for 4 weeks after. Breastfeeding is not advised during treatment, or for 2 weeks after the last Afinitor dose. Everolimus may reduce fertility in both men and women, which is worth raising before starting. Zortress carries a boxed warning, the FDA's most serious kind. Like other anti-rejection drugs, it raises the risk of serious infections and of cancers such as lymphoma and skin cancer, so protective clothing and a high-protection sunscreen matter. It increases the risk of blood clots in the transplanted kidney's blood vessels, mostly in the first month, which can cause loss of the kidney. Combined with full-dose cyclosporine it can damage the kidneys, which is why cyclosporine is given at a reduced dose. In a heart transplant trial it was linked to more deaths in the first three months, and it is not recommended for heart transplants. It can also cause clots in the liver's main artery if started too early, so it is not begun until at least 30 days after a liver transplant.
What everolimus can do depends on why it is used. In cancer it controls rather than cures the disease. In the main breast cancer trial, adding everolimus to exemestane lengthened the typical time before the cancer worsened from about 3 months to about 8 months. In pancreatic neuroendocrine tumors it delayed growth (about 11 months versus 5 on placebo), although the trial did not show that people lived longer. In TSC trials, everolimus shrank kidney angiomyolipomas by at least half in about 4 in 10 adults and SEGA brain tumors by at least half in about a third of patients, compared with none on placebo. For cancer and TSC, treatment usually continues as long as it is helping and side effects remain manageable, with scans to check the response. Expect regular blood tests for blood counts, kidney function, blood sugar and cholesterol, plus trough levels when the dose depends on them. Side effects often lead to a pause or a lower dose rather than stopping for good, and mouth care from the first day makes a real difference. Older adults in the breast cancer trial had more serious side effects and stopped treatment more often, so closer monitoring is common at older ages. After a transplant, Zortress is part of a long-term anti-rejection plan, with frequent level checks early on and whenever other medicines change. Doses should only be changed or stopped by the transplant team, and protecting the skin from the sun becomes a lasting habit.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Everolimus, what you've noticed, or ask the community a question.